Bio-Techne Corporation (TECH)

68.31 +0.26 (+0.38%) At close: 04:00PM EST

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854
https://www.bio-techne.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,200

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Charles R. Kummeth	CEO, President & Director	1.26M	48.58M	1960
Mr. James T. Hippel	Executive VP of Finance & CFO	691.78k	N/A	1971
Mr. Kim Kelderman	Chief Operating Officer	845.71k	126.84k	1967
Mr. Shane Bohnen	Senior VP, General Counsel & Corporate Secretary	353.6k	N/A	1975
Mr. William A. Geist	President of Protein Sciences Segment	533.67k	N/A	1970
David Clair	Senior Director of Investor Relations & Corporate Development	N/A	N/A	N/A
Mr. Gerry Andros	Vice President of Sales and Marketing	N/A	N/A	N/A
Mr. Robert M. Gavin	Vice President of Corporate Development	724.51k	N/A	1968
Ms. Brenda S. Everson	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Mr. Luca Cicchetti	Managing Director	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Bio-Techne Corporation’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.